The activity of Zerbaxa (ceftolozane/tazobactam, or C/T) alone or in combination with other antibiotics shows promise against multi-drug resistant (MDR) Pseudomonas aeruginosa infection in pediatric cystic fibrosis (CF) patients, new research shows. The study, “In vitro Activity of Ceftolozane/Tazobactam Alone or with an Aminoglycoside Against Multi-Drug-Resistant Pseudomonas aeruginosa…
News
Cystic fibrosis (CF) patients have a poorer diversity of gut bacteria than healthy people, and it gets worse as the disease progresses, an Irish study indicates. In addition, patients with severe lung impairment have significantly fewer bacterial species in their gut than those with mild lung problems, researchers found. Because frequent intravenous antibiotic…
Aeolus Pharmaceuticals has released preliminary results from a study suggesting that AEOL 20415 could treat antibiotic-resistant bacteria, protecting the lungs in cystic fibrosis (CF). The company said its drug reduced infection, improved body weight and reduced the presence of white blood cells (macrophages and lymphocytes) in an animal model of CF. Brian Day, PhD,…
Canadians with cystic fibrosis (CF) live 10 years longer than Americans with the disease, a study shows. The life span of the average Canadian with CF was 50.9 years, versus 40.6 years for the average American, according to Anne Stephenson of St. Michael’s Hospital, the lead author of the study.
Using a virus may be a reliable way to treat antibiotic-resistant bacterial infections in cystic fibrosis (CF) patients’ lungs, according to a study. The approach is called phage therapy. Phage is a shortened version of bacteriophage, a virus that infects bacteria. The study, “Phage Therapy Is Highly Effective Against Chronic…
The levels of a protein called calprotectin in the stool could not only be a marker of intestinal disease but could also help determine disease severity in cystic fibrosis (CF), according to a study published in the scientific journal Immunobiology.
Canon BioMedical has developed 21 Novallele genotyping assays that can detect changes within the cystic fibrosis transmembrane conductance regulator (CFTR) — the defective gene in cystic fibrosis (CF) patients. Different types of genetic mutations in the CFTR gene cause diseases. These range from single nucleotide polymorphisms (SNPs, the most common type of…
Data from the recently completed Phase 2 trial of Resunab (JBT-101) for cystic fibrosis (CF) treatment will be available by March 31, Corbus Pharmaceuticals has announced. The study (NCT02465450) included 85 patients who were treated at CF centers in the United States, Belgium, France, Germany, Italy, Poland and…
The University of Pittsburgh has agreed to conduct a Phase 1 and 2 clinical trial of Aries Pharmaceuticals‘ AIR001 for treating Pseudomonas aeruginosa bacteria infections in patients with cystic fibrosis (CF). Researchers from the university and the University of Pittsburgh Medical Center will work together on the open-label safety and proof-of-concept trial. Aries, a…
Vertex Pharmaceuticals is acquiring CTP-656, a potentiator treatment for the protein that is defective in cystic fibrosis, from Concert Pharmaceuticals. CTP-656, a deuterium-modified version of the therapy ivacaftor, is a next-generation cystic fibrosis transmembrane conductance regulator (CFTR) potentiator, meaning that it enhances the activity of the CFTR protein. CTP-656 has received…
Your CF Community
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.